磷酸氯喹治疗阿比多尔治疗失败新冠肺炎患者的疗效观察  

Efficacy of Chloroquine Phosphate in Treatment of COVID-19 Patients in Whom Abidol Treatment has Failed

作　　者：莫广艳[1] 席加喜[1] MO Guangyan;XI Jiaxi(The People's Hospital of Guangxi Zhuang Autonomous Region,Namiing 530000,China)

机构地区：[1]广西壮族自治区人民医院,南宁530000

出　　处：《病毒学报》2020年第5期758-762,共5页Chinese Journal of Virology

摘　　要：2019年底,新型冠状病毒肺炎(Coronavirus disease 2019,COVID-19)于湖北省武汉发现,目前尚无明确的特效药。为观察COVID-19经阿比多尔治疗失败后接受磷酸氯喹治疗的临床疗效,本研究根据入组标准收集了9例阿比多尔治疗失败后接受磷酸氯喹治疗的患者的体温、呼吸道症状、咽拭子核酸、肺部影像学等资料,评价磷酸氯喹治疗后整体的临床有效率,并评价其安全性。结果显示,经磷酸氯喹治疗有8例患者体温、呼吸道症状、咽拭子核酸检测等转归,达到出院标准;1例因核酸持续阳性且肺部CT无明显吸收,考虑治疗效果不佳,整体临床有效率为88.89%。有6例患者出现出现恶心、呕吐、头晕、视力模糊、转氨酶升高等不良反应,考虑与磷酸氯喹相关,停药后均缓解。因此,对于阿比多尔治疗失败新冠肺炎患者可考虑予磷酸氯喹治疗,具有良好的临床疗效,不良反应轻,停药后可缓解。We wished to determine the clinical efficacy of chloroquine phosphate in patients with coronavirus disease 2019(COVID-19)in whom abidol treatment was unsuccessful. Nine patients suffering from COVID-19 were studied. Information on the temperature,respiratory symptoms,nucleic acids(NAs)from SARS-CoV-2 and computed tomography of the lung were collected. The clinical effect was evaluated according to before and after treatment. In eight cases,temperature,respiratory symptoms,pulmonary outcomes,and levels of SARSCoV-2 NAs met the standards for hospital discharge. One patient who was positive for SARS-CoV-2 NAs had poor therapeutic effects and no absorption in the lungs. Treatment with chloroquine phosphate was efficacious in 89% of cases. During treatment,six patients experienced a total of six adverse events(vomiting,nausea,diarrhea,dizziness,blurred vision,increased levels of liver enzymes). The adverse reactions reversed after drug withdrawal.

关 键 词：新型冠状病毒(SARS-CoV-2) 新冠肺炎(COVID-19) 磷酸氯喹 临床疗效 安全性 

分 类 号：R373.1[医药卫生—病原生物学] R511[医药卫生—基础医学]